White House expands drug pricing portal with 600 generic medicines
TrumpRx platform broadens beyond branded pharmaceuticals but questions over affordability impact persist
The White House has added more than 600 generic medicines to TrumpRx.gov, its government-run drug price comparison portal, in an attempt to address a significant gap in the platform's coverage since its launch earlier this year.
The expansion, announced by President Donald Trump on Monday, adds widely-used drugs including the hypertension treatment lisinopril, diabetes standard-of-care metformin, cholesterol medication atorvastatin and blood thinner clopidogrel. The move is notable given that generic drugs account for approximately nine in every ten prescriptions dispensed in the United States, according to Food and Drug Administration estimates — a statistic that had made the portal's initial omission of such medicines a conspicuous oversight.
TrumpRx launched in early 2026 listing only select branded pharmaceuticals whose prices had been reduced under the administration's most favoured nation agenda, which seeks to bring US drug prices into line with the lowest rates paid by comparable high-income countries. The portal does not sell medicines directly to patients but instead enables them to compare cash prices at local pharmacies and through private delivery services. The White House said it has incorporated discounts from Amazon Pharmacy (AMZN), GoodRx (GDRX) and Mark Cuban's Cost Plus Drugs into the platform.
Certain categories of medicine will remain absent from the site. Controlled substances — which would encompass stimulant-based treatments for attention deficit disorders — are excluded, as are drugs subject to FDA-mandated risk evaluation and mitigation strategies and those not commonly available through direct-to-consumer channels.
A lever in a broader campaign
TrumpRx sits at the centre of the administration's pharmaceutical pricing strategy, which has combined the portal with the threat of import tariffs to extract pricing concessions and domestic investment pledges from major drugmakers. Novo Nordisk (NVO), Eli Lilly (LLY), Gilead Sciences (GILD), Roche (RHHBY) and, most recently, Regeneron (REGN) have all reached agreements with the White House. Under those arrangements, 17 large pharmaceutical companies have committed to registering selected products on TrumpRx at discounted prices. Regeneron, for instance, has listed its cholesterol therapy Praluent on the platform.
Other branded medicines currently featured include Novo's GLP-1 treatments Ozempic and Wegovy, fertility drugs from Merck KGaA's (MRK) EMD Serono unit, inhalers from AstraZeneca (AZN) and Pfizer's (PFE) eczema treatment Eucrisa.
Legal and political scrutiny
The portal has attracted controversy since before its debut. Democratic senators Dick Durbin, Peter Welch and Elizabeth Warren wrote to the Department of Health and Human Services' Office of Inspector General in January warning that the site could breach federal anti-kickback statutes. Broader questions about the platform's practical impact on drug affordability for American patients have continued to dog the initiative in the months since its launch.